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Background: Hyperhomocysteinemia (HHCY) is a risk factor for cardiovascular diseases (CVD). HHCY may interact with
hypertension (HTEN) and an unfavorable cholesterol profile (UNFAVCHOL) to alter the risk of CVD.
Objectives: To estimate the prevalences of HHCY (1) isolated and (2) in combination with UNFAVCHOL and/or HTEN in
different age categories. To provide information that may improve the screening and treatment of subjects at risk of CVD.
Design: Cross-sectional data on 12 541 men and 12 948 women aged 20þ y were used from nine European studies.
Results: The prevalence of isolated HHCY was 8.5% in subjects aged 20–40 y, 4.7% in subjects aged 40–60 y and 5.9% in
subjects aged over 60 y. When combining all age groups, 5.3% had isolated HHCY and an additional 5.6% had HHCY in
combination with HTEN and/or UNFAVCHOL. The combinations of risk factors increased with age and, except for
HHCY&UNFAVCHOL, were more prevalent than predicted by chance. Of the young subjects (20–40 y), 24% suffered from
one or more of the investigated CVD risk factors. This figure was 75.1% in the old subjects (60þ years).
Conclusions: A substantial number of subjects in selected European populations have HHCY (10.9%). In half of these cases,
subjects suffer also from other CVD risk factors like UNFAVCHOL and HTEN. Older people in particular tend to have more than
one risk factor. Healthcare professionals should be aware of this when screening and treating older people not only for the
conventional CVD risk factors like UNFAVCHOL and HTEN but also HHCY, as this can easily be reduced through increased intake
of folic acid via supplement or foods fortified with folic acid.
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Introduction
Meta-analyses consistently report that elevated plasma total
homocysteine (tHcy) concentrations increase the risk of
cardiovascular disease (CVD) (The Homocysteine Studies
Collaboration, 2002; Klerk et al, 2002; Wald et al, 2002). A
25% reduction in tHcy concentration (about 3mmol/l) is
estimated to result in an 11% lower risk of ischemic heart
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disease and in a 19% lower risk of stroke (The Homocys-
teine Studies Collaboration, 2002). Hyperhomocysteinemia
(HHCY) is of particular concern in subjects with other risk
factors (de Bree et al, 2002), like those with hypertension
(HTEN) (Vollset et al, 2001) or with an unfavorable
cholesterol profile (UNFAVCHOL) (Graham et al, 1997).
Plasma tHcy concentration correlates weakly with blood
pressure and cholesterol concentration, but in the direction
of an increased risk of CVD, for example, the tHcy
concentration is positively associated with systolic blood
pressure and negatively with the HDL cholesterol concentra-
tion (Alfthan et al, 1994; Brattstrom et al, 1994; Arnesen et al,
1995; Nygard et al, 1995; Malinow et al, 1996; de Bree et al,
2001a). Suffering from more than one of these risk factors
can have an additive or multiplicative effect on the risk of
CVD. The latter finding was reported in the European
Concerted Action Project (Graham et al, 1997).
Information on the prevalence of HHCY in isolation or in
combination with HTEN and/or UNFAVCHOL in European
populations is not available. To obtain such information, a
random sample of the source population is needed. For
practical and financial reasons, this was not possible for the
present study. In order to obtain an reasonable estimate of
these prevalences, available data were combined from
published and unpublished studies. The data presented in
this paper should therefore be seen as an initial estimate of
the prevalences of HHCY, HTEN and UNFAVCHOL in a
nonrandom sample of several European populations. Despite
these limitations, this study gives an important first indica-
tion of the percentage of young, middle-aged and elderly
subjects who are at increased risk of CVD due to HHCY,
either isolated or in combination with UNFAVCHOL and/or
HYPTEN. Such information is important for healthcare
profesionals to influence decisions on screening and treating
people at increased risk of CVD.
Methods
Literature search
A computerized MEDLINE search, 1986 through September
2000, was used to identify studies that measured the tHcy
concentration in general population-based samples. The
search results with ‘homocysteine’ as key-word were com-
bined with the names of the countries of interest, inserted in
the address of author field. In addition, reference lists of all
identified articles were searched for additional relevant
studies.
Study populations
In September 2000, corresponding authors of publications of
interest were contacted with a request for data. In total, over
55 letters and e-mails were sent to authors believed to be
working in Sweden, Germany, UK, Ireland, France, Spain,
Portugal, Italy, Norway, Finland, Denmark, the Netherlands,
Belgium and Austria. Owing to changes in either the
addresses of corresponding authors, the absence of data on
HTEN and/or UNFAVCHOL, diseased populations or unwill-
ingness to provide data, this paper is based on data from nine
different study populations from six different European
countries (Norway, UK, Germany, the Netherlands, Portugal,
France).
Data collection and definition of study variables
On a provided form, the individual study authors could fill
out the number of subjects with HHCY, UNFAVCHOL and
HTEN, and the number of subjects with a combination of
these CVD risk factors.
HHCY was defined as a tHcy concentration 415 mmol/l
(Ueland et al, 1993). As there may be substantial variation in
the measured tHcy concentration between laboratories
(Eliason et al, 1999; Tripodi et al, 2001), we adapted this
cutoff point for those laboratories for which we had
information on the difference in tHcy concentration with
the laboratory of the University of Bergen, Norway that set
the cutoff point. Thus, HHCY in two Dutch studies
(Stehouwer et al, 1998; de Bree et al, 2001b) was defined as
a tHcy concentration 417.4 mmol/l. The method used (te
Poele Pothoff et al, 1995) in these studies showed a
systematic difference of þ2.4 mmol/l compared to the
laboratory in Bergen (de Bree et al, 2001b).
UNFAVCHOL was defined as a total cholesterol level
Z6.5 mmol/l and/or HDL cholesterol level r0.9 mmol/l
and/or the use of cholesterol-lowering medication (European
Atherosclerosis Society, 1987). HTEN was defined as a
diastolic blood pressure Z95 mmHg and/or a systolic blood
pressure Z160 mmHg and/or the use of blood pressure-
lowering medication (Working Group on Risk and High
Blood Pressure, 1985).
The following exceptions were made for the definitions of
UNFAVCHOL and HTEN. Nygard et al (1995) defined
UNFAVCHOL with data based only on the total cholesterol
level and did not have data on blood pressure-lowering
medication. Herrmann et al (1999) defined UNFAVCHOL as
the total cholesterol concentration above 6.21 mmol/l and
defined HTEN only with the use of blood pressure-lowering
medication. Dierkes and Westphal (2000, personal commu-
nication) defined HTEN as systolic blood pressure
4140 mmHg and/or the use of antihypertensive drugs.
Of the nine study populations, three analyzed blood
for tHcy using nonfasting subjects (Nygard et al, 1995;
Stehouwer et al, 1998; de Bree et al, 2001b), whereas in the
six remaining studies, fasting subjects were used (Bates et al,
1997; Herrmann et al, 1999; Hoogeveen et al, 2000; Araujo
et al, 2000; mennen et al, 2002)(Dierkes and Westhal, 2000,
personal communication). For an optimal tHcy measure-
ment, subjects are recommended to be fasting (Refsum et al,
1997). Yet, a recent study contradicts this by showing that
the interindividual variation at 0800 hours in the morning
after an overnight fast is higher (11%) than the variation in
the nonfasting state at 1200 (7.8%) and 1400 (6.8%) hours
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(Fokkema et al, 2003). Therefore, more research is needed to
indicate whether subjects should be fasting or not.
Statistical analyses
For convenience, the data were delivered by the original
investigators as the total number of men and women
(separately for 10-y age classes) with HHCY, UNFAVCHOL,
HTEN and all possible combinations. This means that some
subjects appear in more than one column: for example, a
subject with a combination of HHCY&UNFAVCHOL does
also appear in the column ‘total HHCY’ and in the column
‘total UNFAVCHOL’. In Microsofts excel 97 SR-2, we
calculated the number of subjects with isolated HHCY as
follows: [(ntotal HHCY)((ntotal HHCY&UNFAVCHOLntotal
HHCY&UNFAVCHOL&HTEN)þ (ntotal HHCY&HTENntotal
HHCY&UNFAVCHOL&HTEN)þntotal HHCY&UNFAVCHOL&
HTEN)]. The number of subjects with only HHCY&
UNFAVCHOL was calculated with (ntotal HHCY&
UNFAVCHOL–ntotal HHCY&UNFAVCHOL&HTEN) and the
number of subjects with only HHCY&HTEN with (ntotal
HHCY&HTENntotal HHCY&UNFAVCHOL&HTEN). The
number of subjects with isolated UNFAVCHOL, HTEN and
their isolated combinations was calculated in a similar
manner. These calculations were made for three age classes
(20–40, 40–60 and 60þ years), for men and women separately
and combined.
Note that the contributing authors did not provide
individual data of their study populations; only the number
of subjects above predefined threshold levels was provided. It
was therefore impossible to reanalyze the data with other
definitions for HHCY, UNFAVCHOL and HTEN. Moreover,
due to the lack of individual data, confidence intervals for
our estimates could not be estimated.
If the investigated risk factors occur independently of
each other, the expected prevalence of, for example,
HHCY&UNFAVCHOL¼ (observed total prevalence of
HHCYobserved total prevalence of UNFAVCHOL). If the
risk factors cluster, the prevalence of the combination is
higher than the product of the separate total prevalence
of the risk factors. To analyze whether the combinations
(i) HHCY&UNFAVCHOL, (ii) HHCY&HTEN, (iii) UNFAV-
CHOL&HTEN, (iv) HHCY&UNFAVCHOL&HTEN occurred
more often than expected under the assumption that the
risk factors are independent, loglinear models were used. The
loglinear model treats all variables as response variables and
tests the statistical (in)dependence between them. In these
models, the effect of sex, age (20–40, 40–60, 60þ years) and
study population were controlled for. These analyses were
carried out using the PROC CATMOD procedure of SAS
statistical software (version 6.12) (SAS institute Inc., Cary,
NC, USA).
Results
The number of men and women per study and age class is
given in Table 1. The majority of subjects were between 40
and 60 y. The largest number of data was derived from the
Hordaland study in Norway, whereas the smallest number of
data came from Portugal. Overall, the number of men and
women was equal. Table 2 presents data on the mean levels
of the CVD risk factors and the total prevalences of HHCY,
HTEN and UNFAVCHOL per study, for men and women
separately. Differences in mean levels or prevalences were
partly due to true differences between countries with risk
factor levels generally lower in Southern vs Northern European
countries. However, they also reflected the different criteria
used for selection of the original study population. The
Table 1 Number of men and women in each age class in the nine study populations
Men Women
Country, name of study (when given) Reference
N
Total
20–40 y
( N)
40–60 y
( N)
60þ y
( N)
20–40 y
( N)
40–60 y
( N)
60þ y
( N)
Norway, Hordaland Study Nygard et al (1995)a 18 044 6382 2191 6756 2715
UK, National Diet and Nutrition Survey Bates et al (1997)b 470 259 211
Germany Herrmann et al (1999)c 267 12 1 79 30 4 141
Germany Dierkes & Westhal (2000) 82 12 20 50
The Netherlands, Hoorn Study Hoogeveen et al (2000)d 631 121 183 76 251
The Netherlands, MORGEN study De Bree et al (2001)a 3025 719 718 56 718 718 96
The Netherlands, Zutphen Study Stehouwer et al (1998) 878 878
Portugal Araujo et al (2000)e 101 31 39 1 16 13 1
France, SUVIMAX Study Mennen et al (2002) 1991 691 168 35 991 106
Total 25 489 762 7964 3815 819 8608 3521
Compared to the original publication:
aabout 2000 extra subjects were included;
bonly the free living subjects were included;
cabout 200 subjects were not included;
donly the control subjects were included;
eonly the blood donors were included and about 80 extra blood donors were included.
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Table 2 Mean plasma THcy concentration, diastolic and systolic blood pressure, total and HDL cholesterol concentration and total prevalences of HHCY, HTEN and UNFAVCHOL in the nine
study populations
Men (n¼12 541) Women (n¼12 948)
Country, Ref (see table legend)
THcy
(mmol/l)
HHCY
(%)
Diabp
(mmHg)
Sysbp
(mmHg)
HTEN
(%)
Totchol
(mmol/l)
HDL
(mmol/l)
UNFAVCHOL
(%)
THcy
(mmol/l)
HHCY
(%)
Diabp
(mmHg)
Sysbp
(mmHg)
HTEN
(%)
Totchol
(mmol/l)
HDL
(mmol/l)
UNFAV
CHOL (%)
Norway, 1a 11.8 11.4 82.8 138.2 20.5 5.9 NA 26.6 10.2 6.9 79.1 131.9 17.1 5.9 NA 28.1
UK, 2b 15.7 50.2 NA NA 53.3 NA NA 44.4 14.7 34.1 NA NA 65.9 NA NA 49.3
Germany, 3c 15.1d 28.3 NA NA 4.3 NA NA 22.8 15.1d 32.0 NA NA 13.1 NA NA 26.3
Germany, 4 NA 16.7 NA NA 0 NA NA 33.3 NA 8.6 NA NA 11.4 NA NA 17.1
The Netherlands, 5e 11.5d 26.6 82d 139d 34.2 6.7d 1.3d 54.3 11.5d 14.4 82d 139d 42.5 6.7d 1.3d 62.7
The Netherlands, 6 14.6 14.4 79.7 124.3 11.0 5.2 1.2 26.7 13.1 8.9 75.8 117.9 10.1 5.2 1.5 15.7
The Netherlands, 7 15.9 25.1 85.5 151.1 42.4 6.1 1.1 26.4 — — — — — — — —
Portugal, 8f 9.0d 5.6 NA NA 5.6 NA NA 39.4 9.0d 3.3 NA NA 6.7 NA NA 10.0
France, 9 10.8 12.6 83.8 130.3 13.2 5.9 NA 27.5 8.7 3.9 77.9 121.5 4.2 5.7 NA 21.7
Mean and 12.4 82.7 136.9 5.8 1.2 10.6 86.5 142.4 5.8 1.5
range 9.0–15.9 79.7–85.5 124.3–151.1 5.2–6.7 1.1–1.3 8.7–15.1 75.8–79.1 117.9–139 5.2–6.7 1.3–1.5
1—Nygard et al (1995); 2—Bates et al (1997); 3—Herrmann et al (1999); 4—Dierkes & Westhal (2000); 5—Hoogeveen et al (2000); 6—De Bree et al (2001a); 7—Stehouwer et al (1998); 8—Araujo et al
(2000); 9—Mennen et al (2002).
THcy¼ total homocysteine concentration; HHCY¼hyperhomocysteinemia; Diabp¼diastolic blood pressure; Sysbp¼ systolic blood pressure; HTEN¼hypertension; Totchol¼ total cholesterol
concentration; HDL¼HDL cholesterol concentration; UNFAVCHOL¼unfavorable cholesterol profile; NA¼No information available on these mean levels in the original publication (or data on the
prevalences only were provided as personal communication).
aCompared to the original publication about 2000 extra subjects were included.
bOnly the values of the free living subjects of this population were included.
cCompared to the original publication about 200 subjects were not included.
dMean value of men and women together.
eOnly the values of the control subjects of this population were included.
fOnly the values of blood donors were included and compared to the original publication, about 80 extra blood donors were included.
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prevalence of risk factors was high in the UK study, but this was
an elderly population. Thus, Table 2 should be interpreted in
conjunction with Table 1.
The prevalence of total HHCY, HTEN and UNFAVCHOL
within each study was higher in men than in women
(Table 2), but the relation between age and the prevalence
of these CVD risk factors was in general not different for men
and women; therefore we combined men and women for the
analysis on all European data. Figure 1 shows that with
increasing age, the prevalence of isolated HHCY decreased
somewhat. This result was caused by a relatively high
prevalence of isolated HHCY (9.2%) in Dutch adults aged
20–40 y of the MORGEN study, providing 91% of the data in
this age group. The prevalence of isolated UNFAVCHOL and
isolated HTEN increased with increasing age, and the same
was true for all possible combinations of the risk factors. The
high prevalence of UNFAVCHOL&HTEN in the age category
60þ y, was mainly due to a high prevalence (26%) in
Norwegian women. Without the data of the Hordaland study,
the prevalence of UNFAVCHOL&HTEN was only 10.3%.
The total prevalence of the CVD risk factors in the total
European study population can be derived by adding up the
data in Figure 1. The total prevalence of HHCY was 10.7%
(8.5þ1.8þ0.3þ0.1) in the age category 20–40 y, 7.3% in the
age category 40–60 y and 19.2% in the age category 60þ y.
The total prevalence of UNFAVCHOL rose with age from 13.2
via 19.2 to 49.3%, and that of HTEN from 3.2 via 10.0 to
42.1%, in the respective age groups. Although the preva-
lences in some age groups were influenced by the data of the
largest study populations, Table 3 shows that the isolated
prevalences of HHCY, UNFAVCHOL and HTEN were compar-
able after exclusion of the data of the Dutch and Norwegian
data. The total prevalences increased after exclusion of the
larger studies, with a maximum increase of 7.2%.
Figure 2 summarizes the data according to the prevalence
of the number (0–3) of CVD risk factors, independent of
whether this was HHCY, UNFAVCHOL and/or HTEN. The
prevalence of at least one CVD risk factor increased with age.
In the 20–40 y age category, 76% of the population had no
risk factor, contrasted with only 24.9% in the oldest age
category. Nearly no subject in the youngest age category had
three risk factors, whereas 4.6% of the older subjects did so.
Table 4 shows the expected and observed values of the
various combinations of the three CVD risk factors. To
calculate the expected values, the observed total prevalences
of HHCY, UNFAVCHOL, HTEN are required (given in the
table). After adjustments for age, sex and study center, the
combinations HHCY&HTEN and UNFAVCHOL&HTEN oc-
curred more often than was expected on the basis of chance
(Po0.0001), as did the combination HHCY&UNFAVCHOL&
HTEN (P¼0.003). There was no clustering of HHCY and
UNFAVCHOL (P¼0.4).
Discussion
Our data indicate that one out of every nine subjects (10.
9%) in these European populations suffers from HHCY. In
half of these cases (5.6%), these subjects also have
UNFAVCHOL and/or HTEN. The combinations of HHCY
with UNFAVCHOL and/or HTEN all increased with age,
confirming that elderly people in particular suffer from more
than one CVD risk factor.
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Figure 1 Prevalence of isolated hyperhomocysteinemia (HHCY), isolated unfavorable cholesterol profile (UNFAVCHOL), isolated hypertension
(HTEN) and combinations of these risk factors in European men and women, stratified by age.
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To judge these data properly, it is important to first discuss
some internal validity aspects. For an optimal tHcy measure-
ment, whole blood should be cooled immediately or should
be centrifuged within 1 h after drawing. At room tempera-
ture, the blood cells will continue to export homocysteine to
plasma (Andersson et al, 1992; Malinow et al, 1994), leading
to artificially higher tHcy concentrations (de Bree et al,
2001b). Two studies did not treat whole blood according to
this recommendation (Stehouwer et al, 1998; Mennen et al,
2002). This did not greatly affect our estimates: the
prevalence of total HHCY was 10.6% in the studies that
centrifuged blood within 1 h vs and 12.9% in those that did
Table 3 Isolated and total prevalences of HHCY, UNFAVCHOL and HTEN in European men and women (aged 20þ y), with and without the inclusion of
the two largest studies
Isolated prevalences Total prevalences
HHCY UNFAVCHOL HTEN HHCY UNFAVCHOL HTEN
All studies (n¼25 489) 5.3 16.6 8.6 10.9 27.4 18.8
Without the MORGEN study (n¼22 464) 4.9 16.9 9.0 10.8 28.3 19.9
Without the Hordaland study (n¼7445) 7.4 16.7 8.5 15.4 27.6 19.0
Without both the MORGEN and the Hordaland study (n¼4420) 7.4 18.2 10.5 18.0 32.0 24.7
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Figure 2 Prevalence of CVD risk factors (HHCY, UNFAVCHOL and/or HTEN) in European men and women, stratified by age. No risk
factors¼no HHCY, no UNFAVCHOL and no HTEN; 1 risk factor¼ either HHCY, UNFAVCHOL or HTEN; 2 risk factors¼ either
HHCY&UNFAVCHOL, UNFAVCHOL&HTEN or HHCY&HTEN; 3 risk factors¼HHCY&UNFAVCHOL&HTEN.
Table 4 Comparison of expected and observed prevalences of combinations of HHCY, UNFAVCHOL and HTEN
Expected values Observed values (see Figure 4)
Total HHCY (5.3þ2.3þ1.7þ1.5)¼10.8%
Total UNFAVCHOL (16.7þ6.9þ2.3þ1.5)¼27.4%
Total HTEN (8.6þ6.9þ1.7þ1.5)¼18.7%
Total HHCY&UNFAVCHOL 100*(0.1080.274)¼3.0% Total HHCY&UNFAVCHOL 3.9%
Total UNFAVCHOL&HTEN 100*(0.2740.187)¼5.1% Total UNFAVCHOL&HTEN 8.4%*
Total HHCY&HTEN 100*(0.1080.187)¼2.0% Total HHCY&HTEN 3.2%*
Total HHCY&UNFAVCHOL&HTEN 100*(0.1080.2740.187)¼0.6% Total HHCY&UNFAVCHOL&HTEN 1.5%*
*The observed prevalence of this combination is statistically significantly (Po0.004) higher than the expected values. For these analyses we used loglinear models in
which we adjusted for age, sex and study center (see Methods).
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not. Furthermore, there is the effect of measurement errors
and intraindividual variation. The risk factors in the
included studies were only measured once, as is usually
done in large-scale studies, this will have led to an over-
estimation of the number of subjects above the chosen
threshold levels. Finally, three studies applied other defini-
tions of UNFAVCHOL and HTEN (Nygard et al, 1995;
Herrmann et al, 1999) (Dierkes and Westhal, 2000, personal
communication). This has led to a difference in the estimate
for isolated UNFAVCHOL only, which was lower in the 40–
60 y old category (13.2 vs 19.7% in the studies that did not vs
did use our definitions), but higher in the oldest age category
(25.3 vs 16.6%). An underestimation was expected as these
studies (Herrmann et al, 1999; Nygard et al, 1995) did not
have data on the HDL-cholesterol level. However, it is known
that the cholesterol concentration is, in general, higher in
Northern than in Southern European countries (Verschuren
et al, 1995), and it is particularly high in Norway (Johansson
et al, 1996).
Secondly, it is important to discuss to what extent these
data can be generalized to the ‘European population.’ Firstly,
for this inventory, as many studies as possible were identified
that contained relevant data. However, due to reasons
described in Methods, the final number of included studies
was low (nine out of 55). However, the data of two of the
largest surveys in Europe were used, in which the plasma
tHcy concentration was measured (Nygard et al, 1995; de
Bree et al, 2001b). More importantly, with or without these
data, the isolated prevalences of HHCY, UNFAVCHOL and
HTEN did not materially change. Nevertheless, the total
prevalences increased. Thus, it seems likely that with the
inclusion of the two large surveys, an overestimation of the
presence of CVD risk factors has been prevented. On the
other hand, the participants of the original studies included
in this inventory were volunteers. Generally, individuals
who volunteer for these types of studies tend to be healthier
than those who do not volunteer, due to a generally more
favorable lifestyle profile (Verschuren et al, 1993). Using a
true random sample of the European population would
almost certainly result in higher prevalences of the investi-
gated CVD risk factors. Thus, despite the fact that a single
determination of the risk factors will have overestimated our
prevalences, it is reasonable to assume that an underestimate
rather than overestimate of the actual prevalence of the
studied CVD risk factors has taken place.
Standardized protocols and international calibration pro-
grams exist (and were applied) for the measurement of
cholesterol and blood pressure. A cutoff value of 15 mmol/l
was chosen for the tHcy concentration, which is the most
widely accepted definition of HHCY in Europe (Ueland et al,
1993). Note that the lack of standardization programs
applied for the tHcy measurement results in considerable
(6 to 15%) interlaboratory variation of the measured tHcy
concentration of one sample (Eliason et al, 1999; Moller et al,
1997, 1999; Pfeiffer et al, 1999; Tripodi et al, 2001). For most,
except two (de Bree et al, 2001b; Stehouwer et al, 1998) (see
Methods) studies, no data were available on how the tHcy
measurement in those studies related to the laboratory that
set the cutoff value (Ueland et al, 1993). Thus, from a
practical point of view, it was necessary to ignore the
interlaboratory variation and use the cutoff value of
15 mmol/l. The cutoff values used to define UNFAVCHOL
and HTEN were, at the time that the subjects were
investigated, used by clinicians as a threshold to initiate
medical treatment, which makes them the most suitable
cutoff values for these data (Working Group on Risk and
High Blood Pressure, 1985; European Atherosclerosis Society,
1987). Note, however, that if this study would be performed
nowadays, current guidelines would be applied. Nowadays,
treatment is based on the total risk profile of a person
(including sex, age, total, HDL and LDL cholesterol, blood
pressure, diabetes, smoking and family history or premature
CVD) and is focused on ‘desirable’ levels of CVD risk factors
rather than cutoff values for increased levels. Using recent
guidelines for a desirable tHcy concentration (o10–12 mmol/
l; Malinow et al, 1999; Graham et al, 1997; Stanger et al,
2003), blood pressure (diastolic blood pressure o90 mmHg
and systolic blood pressure o140 mmHg; Kjeldsen et al,
2002) and cholesterol profile (total/HDL ratior5; ATP III,
2001) will identify more subjects that may benefit from
treatment that lowers their CVD risk factor levels.
There are consistent reports on a weak but statistically
significant correlation between tHcy and other CVD risk
factors (rarely above 0.2) (Alfthan et al, 1994; Brattstrom et al,
1994; Arnesen et al, 1995; Nygard et al, 1995; Malinow et al,
1996; de Bree et al, 2001a). Despite this large degree of
independence on a continuous scale, we showed that the
CVD risk factors cluster above defined threshold levels. This
can be explained by various mechanisms, for example,
HHCY may disturb the endogenous sterol response pathway,
leading to increased hepatic biosynthesis and uptake of
cholesterol and triglycerides (Werstuck et al, 2001). Other
explanations include an underlying common lifestyle, a
condition provoking HHCY and other components of the
CVD risk profile such as renal failure or diabetes, or the fact
that some drugs in CVD therapy increase the tHcy concen-
tration (de Lorgeril et al, 1999; Dierkes et al, 1999; Westphal
et al, 2001). A large European case–control study showed that
the plasma tHcy concentration and conventional risk factors
such as smoking and HTEN interact to affect the risk of CVD.
This was shown by the fact that the odds ratio for CVD of
subjects with HHCY in combination with HTEN was 11.3,
whereas based on an additive interaction the expected odds
ratio would have been 5.4 (Graham et al, 1997).
This inventory showed that 10.7% of the Europeans
studied aged 20–40 y, 7.3% aged 40–60 y and 19.2% aged
60þ y have HHCY either isolated or in combination with
UNFAVCHOL and/or HTEN. In addition, 76% of the elderly
have more than one of the investigated CVD risk factors,
whereas 75% of the younger adults have none. This is
important information for healthcare professionals who
may, based on these results, decide to routinely screen the
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elderly for HTEN, UNFAVCHOL and HHCY. Targeted treat-
ment of the risk factors present may consequently minimize
the risk of CVD. The same approach is probably less cost-
effective in younger subjects, and screening may only be
adopted if there are additional indications, such as family
history of CVD or an underlying disease.
The treatment chosen depends on the type of risk factor
and the degree to which it is increased. Under well-
controlled conditions, dietary interventions have been
succesful in treating HHCY (Brouwer et al, 1999; Riddell
et al, 2000; Ashfield-Watt et al, 2003), UNFAVCHOL (Hu et al,
2001) and HTEN (Appel et al, 1997). However, some of the
intervention diets required extreme adaptations in the
dietary habits of the subjects (eg consuming 45 servings of
fruit/day; Appel et al, 1997) and may not be suitable in a
‘free-living’ situation. This is why extremely elevated total
cholesterol levels and blood pressure are mostly treated with
medications (like statins/fibrates and diuretics/beta-blockers,
etc), but these are expensive and may have unwanted side-
effects. On the other hand, even extremenly high tHcy
concentrations can be lowered with the safe, inexpensive
and effective therapy of folic acid supplementation or the
consumption of fortified foods.
Following the guidelines of the American Heart Associa-
tion, several European countries (Germany, Austria, Switser-
land and the Netherlands) have adopted guidelines to screen
for HHCY in subjects with a risk profile predisposing to a
higher CVD risk (Netherlands Heart Foundation, 2001;
Stanger et al, 2003), like those with UNFAVCHOL, HYPTEN
and smokers. In case of HHCY, a daily dose of B500 (200–
800) mg of folic acid (possibly in combination with vitamin
B6 and B12) may be prescribed alongside a traditional
treatment of their other risk factors (Netherlands Heart
Foundation, 2001; Stanger et al, 2003). Such a dose would on
average lower the tHcy concentration with 25% (B3mmol/l)
(Clarke and Armitage, 2000; van Oort et al, 2003), which in
turn may lower their risk of ischemic heart disease with 11%
and of stroke with 19% (The Homocysteine Studies Colla-
boration, 2002).
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